Alder Biopharma (ALDR)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
18.88 -0.04 (-0.21%) 10/21/19 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 18.88 unch (unch) -
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -296,429 | -288,879 | -156,254 | -85,470 | 8,908 |
| Depreciation Amortization | 2,567 | 3,001 | 1,674 | 751 | 701 |
| Accounts receivable | N/A | N/A | N/A | 113 | 203 |
| Accounts payable and accrued liabilities | 1,273 | -2,395 | 5,488 | 2,816 | -312 |
| Other Working Capital | 8,258 | 36,287 | -18,606 | -2,670 | -58,518 |
| Other Operating Activity | 33,481 | 25,369 | 8,011 | 3,227 | 1,361 |
| Operating Cash Flow | $-250,850 | $-226,617 | $-159,687 | $-81,233 | $-47,657 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -3,136 | -2,050 | -6,614 | -1,223 | -649 |
| Purchase Of Investment | -522,795 | -305,540 | -165,871 | -185,629 | -11,045 |
| Sale Of Investment | 404,813 | 341,970 | 104,765 | 19,585 | 1,960 |
| Investing Cash Flow | $-121,118 | $34,380 | $-67,720 | $-167,267 | $-9,734 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 277,656 | 0 | 0 | N/A | N/A |
| Common Stock Issued | 2,571 | 162,917 | 137,110 | 408,170 | 81,018 |
| Other Financing Activity | 97,710 | 0 | 0 | 36 | -36 |
| Financing Cash Flow | $377,937 | $162,917 | $137,110 | $408,206 | $80,982 |
| Exchange Rate Effect | N/A | N/A | 21 | -9 | -23 |
| Beginning Cash Position | 86,896 | 116,216 | 206,492 | 46,795 | 23,227 |
| End Cash Position | 92,865 | 86,896 | 116,216 | 206,492 | 46,795 |
| Net Cash Flow | $5,969 | $-29,320 | $-90,276 | $159,697 | $23,568 |
| Free Cash Flow | |||||
| Operating Cash Flow | -250,850 | -226,617 | -159,687 | -81,233 | -47,657 |
| Capital Expenditure | -3,136 | -2,050 | -6,619 | -1,223 | -649 |
| Free Cash Flow | -253,986 | -228,667 | -166,306 | -82,456 | -48,306 |